there are a lot of great studies with immuno therapy. the scientists are having a tough time getting to the can aer is. the cancer cells are surrounded by shell, a cocoon. by immuno therapy you can get to those and the treatment. a lot of exciting things going on. >> i go to the doctor tomorrow and what should i ask for? >> the ca19-9. if you say pancreatic cancer they will do this. >> it is not that effective. that's a shame. i have seen it on my blood panel. >> it is not that effective. we don't have an answer yet. we can find it sometimes on a cat scan coincidentally looking for something else. we have to think about if there is a family history. one other point, the pancreas is a double organ so people are not confused. today we are talking about the other side of the pancreas called the exocrine side. it is the part of the gland that makes dais stiff hormones that gets in trouble. >> this is what he is talking about and it is not available. it is coming from copenhagen. i wanted to say that because it is funny. copenhagen and the sc

immuno oncology, that's the buzz word. that buzz could get a lot louder as new drugs start coming to market. immuno oncology is basically cancer treatments 2.0. we're talking about a new class of therapies that use your own immune system to target cancer cells. coupled with more traditional therapies, they could help prevent relapses. analysts are basically calling this a paradigm shift in the way we treat cancer. but we're still very, very early stages for these drugs. a number of companies involved including merck. of course, the biggest player, bristol-myers squibb. it shed its joint diabetes venture last month to focus on it. one of the few drugs already on the market. a promising lung cancer drug in late-stage testing. investors keeping an eye on that. tomorrow the company reports earnings before the bell. analysts saying immuno oncology will not be a big piece of those numbers, but it will be a buzz word when looking for forward guidance in 2014. back to you guys. >> all right, morgan. thanks. stay with us if you wou

the treatment we're studying now at stanford, oral immuno therapy.ones interested in that new therapy. there are centers across america and the world looking at it. >> how does it work? >> to give a tiny amount of ll a food, tell the patient a speck of a speck. >> that you're allergic to? >> yes. >> it is scary, and there are reactions at first. always needs to be done in a hospital setting and it is research. the idea is when you increase doses progressively, you induce a state of desensitization. you won't reaction to the dose you are given. the hope is after many years, your body will understand you're not allergic, for example, peanuts, and you will go off therapy and not react any more. >> have you had any success? >> we're at the stage showing it can be safely done. we're able to desen sitize. you can't do it alone, this is research, it is experimental, and there are reactions. every time we increase the dose, has to be in the hospital in research setting to treat people. sometimes we have to give epinephrine when we increase doses bought they

so immuno ompgology, cancer treatments 2.1. class of therapies using your own immune system to target cancer cells coupled with nor traditional therapy could have prevent relapses and analysts say they represent a complete paradigm shift in how cancer is treated moving forward. we're still in very early stages for these drugs. bristol-myers squibb the pioneer here. shed its diabetes joint venture last month to focus on immunooncology. bmy one of the few drugs on the market. the company has a promising lung cancer drug. that's in stage testing. others with similar late-stage drugs, roche, merck, as 'stro zenica getting involved and some of the biotechs, several propositions, products in earlier stages. a small biotech, parse nehring with glaxosmithkline on melanoma treatments. others, selldex, and others, recently announcing it will increainr rnd spending. >> nicely done, morgan. all those pronunciations. >>> microsoft leads the list of names reportings after the bell and a lot of the focus remains on the new ceo and the search

one of the most devastating problems with cholera is it can go quickly amongst patients who are immuno-suppressed, like our children with malnutrition, and it can cause high, high mortality in this population. so we quickly had to isolate the kids and adults who had cholera. we built a center with beds and iv bags hanging from the roof for the patients who were suffering that were adults. we removed the children with tuberculosis from our isolation tent, and put our children with cholera in this tent. then we built a chlorine bath all around. we burned all their clothes-- anything that potentially could have cholera, we burned it. we built a special latrine for their waste. and we tried to isolate them as much as possible while, at the same time, providing very intensive care for their dehydration, which is the critical problem in cholera. it's a disease that comes on within a few days of incubation, and may only last a few days. but within those three days, you can lose half your weight in diarrhea, and critically need support. iv fluids, oral rehydration fluids-- all of that plus the antibiotic

cdc, but to name a few, kids under 2 years of age, adults over 65, pregnant women, people who are immunotheir doctor right away. >> if you feel it coming on, call the doctor. >> and it comes on fast and furious. you probably will suspect it. within three to six hours, high fevers, headaches, severe body aches, cough, sore throat. feels like you got hit by a truck. >> and unfortunately, they end up in the hospital or often fatal cases. >> that is a potential complication. >> perhaps not related, but the fda has a new recommendation about acediminifin. >> correct. recommendations to physicians to not prescribe combination medication that contains more than 325 milligrams of acediminifin. there are some with higher doses than that. the reason for this, it's been found to be linked to fatal cases of liver disease, liver damage, liver failure and death. nearly half of all cases of liver failure are now attributed to the inadvertent overdose of these prescription medications. >> over the counter, the acce acediminifin is about 200 milligrams or so. >> usually 325, but also comes in a 500 milli